Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study

Table 2 Multivariate analysis of predictors affecting progression-free survival

Multivariate analysis (N = 135)	HR	95% CI for HR		p-value
Variable name	HR	95% CI for HR		p-value
Age	0.992	0.976	1.008	0.309
Sex	1.112	0.583	2.121	0.747
Smoking status	0.793	0.391	1.612	0.522
ECOG status	1.579	0.996	2.504	0.052
Histology (Adenocarcinoma vs others)	1.540	0.344	6.894	0.572
EGFR mutation (19del vs others)	0.965	0.662	1.407	0.853
EGFR treatment (Gefitinib vs others)	1.033	0.699	1.528	0.869
Metastatic status	0.709	0.477	1.052	0.088
Clinical stage (Recurrence vs IV)	0.665	0.383	1.156	0.148
Brain metastasis	0.772	0.512	1.163	0.216
Use of SBRT	0.617	0.408	0.935	0.023

HR Hazard Ratio, CI confidence interval, ECOG eastern cooperative oncology group, EGFR epidermal growth factor receptor, SBRT stereotactic body radiation therapy

ISSN: 1471-2407